StudyFinder

Search Results

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

571 Study Matches

A Review of the Carbon Labeling Landscape and Consumer Attitudes Towards Comparison Carbon Labeling Designs

A carbon label displays the carbon footprint of the product (a number, e.g., 1.18 kg CO2) and helps consumers understand the impact of the product on the environment. The purpose of this study is to understand Penn State students’ preferred method of carbon labeling for a senior thesis. The study will be conducted via a survey that takes less than 5 minutes and requires no personal identifying information.

The participants will complete one survey that takes less than 5 minutes to complete. The survey can be taken on a personal device or a Penn State computer.

No
 

Jillian Wagner
Jillian Wagner - at jpw5858@psu.edu or 614-937-8172
Division of Undergraduate Studies (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
STUDY00021525
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
18 years or older

Exclusion Criteria:
Less than 18 years old
Education, Mental & Behavioral Health, Language & Linguistics
Not applicable
I'm interested
Share via email

The Effects of Aircraft Seat Width on Passenger Comfort

The objective of this research is to determine the relationship between aircraft seat width and passenger comfort. Airlines are reducing the sizes of seats and improving their ability to fly planes at or near capacity. The combined effect is to decrease the quality of the experience of passengers. This work will help us to understand the degree to which comfort has been reduced.

Yes
 

Matthew Parkinson
Ritwik Biswas - at AirplaneResearch@psu.edu
School of Engineering Design and Innovation (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00012135
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
We are particularly interested in small and large participants.
You must be a healthy adult aged 18 years or older.

Exclusion Criteria:
Individuals under 18 years of age are not eligible.
Muscle & Bone, Mental & Behavioral Health
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
State College, PA ,

COVID-19 and microvascular function

This study will investigate the link between previous COVID-19 infection and future heart disease risk.

Yes
 

Lacy Alexander
Gabrielle Dillon - at GAD27@psu.edu or 814-863-8556
Kinesiology (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00018746
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
18-70 years of age
HAD COVID-19
DID NOT HAVE COVID-19
Non-Obese
Non-Smoker

Exclusion Criteria:
Tobacco consumption (e.g. smoking)
Pregnant and/or breastfeeding
Taking blood pressure medication
COVID-19, Heart & Vascular
I'm interested
Share via email
Show 4 locations

Study Locations

Hide all locations
Location Contacts
Altoona, PA ,
Harrisburg, PA ,
State College, PA ,
Williamsport, PA ,

Randomized Phase III Trial of MEDI4736 (durvalumab) asConcurrent and Consolidative Therapy or ConsolidativeTherapy Alone for Unresectable Stage 3 NSCLC (EA5181) (PSCI# 21-041).

The purpose of this study is to compare the usual approach of chemo/radiation followed by one year of MEDI4736 (durvalumab) to chemo/radiation with MEDI4736 (durvalumab) followed by one year of MEDI4736 (durvalumab). The addition of MEDI4736 (durvalumab) during chemo/radiation could prevent your cancer from returning and extend your life. But, it could also cause side effects.This study will help the study doctors find out if this different approach is better, the same, or worse than the usual approach. To decide if it is better, the study doctors will be looking to see if the study drug extends the life of patients and/or prevents the tumor from coming back as compared to the usual approach.This drug, MEDI4736 (durvalumab), is already approved by the FDA for use in other cancers, and for use in your type of cancer after the completion of chemotherapy and radiation. At this time MEDI4736 (durvalumab) is not yet approved (experimental) when given with chemotherapy and radiation. There will be about 660 people taking part in this study.

The purpose of this study is to compare the usual approach of chemo/radiation followed by one year of MEDI4736 (durvalumab) to chemo/radiation with MEDI4736 (durvalumab) followed by one year of MEDI4736 (durvalumab). The addition of MEDI4736 (durvalumab) during chemo/radiation could prevent your cancer from returning and extend your life. But, it could also cause side effects.This study will help the study doctors find out if this different approach is better, the same, or worse than the usual approach. To decide if it is better, the study doctors will be looking to see if the study drug extends the life of patients and/or prevents the tumor from coming back as compared to the usual approach.This drug, MEDI4736 (durvalumab), is already approved by the FDA for use in other cancers, and for use in your type of cancer after the completion of chemotherapy and radiation. At this time MEDI4736 (durvalumab) is not yet approved (experimental) when given with chemotherapy and radiation. There will be about 660 people taking part in this study.

Yes
 

Patrick Ma
PSCI-CTO@pennstatehealth.psu.edu 717-531-5471
Medicine: Hematology and Medical Oncology (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT04092283
SITE00000978
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Patient must be = 18 years old.
Patient must have an ECOG Performance Status of 0 or 1.
Body weight > 30 kg of patients.
Patient must not have unintentional weight loss > 10% within 30 days prior to registration.
Patient must have a baseline ECG obtained within 6 weeks of registration.

Exclusion Criteria:
Patient must not have any active, known or suspected autoimmune disease and neuromuscular paraneoplastic syndromes
Patient must not have a history of active hepatitis B (chronic or acute) or hepatitis C infection.
Patient must not have a known active tuberculosis infection.
Patient must not have any severe infections within 4 weeks prior to registration including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia.
Patient must not have signs or symptoms of severe infection (sepsis) within 2 weeks prior registration.
Cancer
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Centre County COVID-19 Data 4 Action Study

The purpose of this research is to evaluate the extent of COVID-19 risk and perceived risk among Centre County residents and students, and how those risks evolve from the time isolation guidelines were implemented through a return to normal functioning.Participants in this research will complete an electronic survey with questions about their demographic, about their exposure to COVID-19, and about how COVID-19 has affected their health and work/education. Data from this research will be used to inform Centre County planning authorities and the Pennsylvania State University about the needs of communities, including needs for information dissemination and for potentially actionable, local interventions in response to the COVID-19 pandemic.

No
 

Susan McHale
Susan McHale - at src-ssri@psu.edu
Human Development and Family Studies (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00015115
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
At least 18 years of age.
Currently living in Centre County, PA.
Expect to continue living in Centre County, PA (through at least Sept 2020)
Capable of providing your own informed consent.

Exclusion Criteria:
No additional exclusion criteria beyond those required for inclusion.
Infectious Diseases & Immune System, Men's Health, Women's Health
I'm interested
Share via email

KEYSTROKE: A RANDOMIZED PHASE II STUDY OF PEMBROLIZUMAB (KEYTRUDA®) PLUS STEREOTACTIC RE-IRRADIATION VERSUS SBRT ALONE FOR LOCOREGIONALLY RECURRENT OR SECOND PRIMARY HEAD AND NECK CARCINOMA

Study of Pembrolizumab (KEYTRUDA®) Plus non-surgical radiation therapy Versus non-surgical radiation therapy alone for Recurrent or Second Primary Head and Neck Cancer. This study is evaluating the safety of the addition of pembrolizumab to non-surgical radiation therapy.

The purpose of this voluntary research study is to compare any good and bad effects of using the study drug, pembrolizumab, plus radiation therapy to using radiation therapy alone. The addition of the study drug to radiation could shrink your cancer/prevent it from returning but it could also cause side effects.

Yes
 

Mitchell Machtay
igeier@pennstatehealth.psu.edu
Medicine: Hematology and Medical Oncology (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03546582
STUDY00017112
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Confirmed diagnosis of recurrent or any new primary squamous cell carcinoma of the head and neck
Patients for whom resection would be medically contraindicated and/or would impose excessive surgical risk
Patients must have had prior radiation to the head and neck

Exclusion Criteria:
Patients with distant metastases
Tumors that involve more than 180 degrees of the carotid artery
Patients with tumor ulceration through the skin
Disease that requires two or more discontiguous target volumes will be ineligible.
Cancer
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Multimodal brain MRI-guided understanding of non-motor outcomes in Parkinson's post DBS

This study will explore the relationship between multimodal brain MRI findings and cognitive/mood outcomes in Parkinson's Disease (PD) patients following Deep Brain Stimulation (DBS). Patients already planning to undergo DBS for PD who choose to take part in this study will have study visits before and after DBS to collect motor, neurobehavioral and physical therapy measurements.

Patients who are already planning to undergo DBS for PD who choose to take part in this study will have study visits before and after DBS surgery to collect motor, neurobehavioral and physical therapy measurements. While many of these components are part of as standard of care, some assessments will need to be collected specifically for research purposes. There are two in-person visits (one before DBS surgery and one approximately 3-6 months after surgery). As part of the study, an MRI to gather data to answer our research questions will be conducted. This is in addition to the clinical MRI that is part of the regular assessment to determine if an individual is suitable for the DBS surgery.

$130 if components of study are completed

Yes
 

Sol De Jesus
Amanda Snyder - at TBRC@pennstatehealth.psu.edu or 717-531-5233
Neurology (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
STUDY00016574
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Age at least 18
Diagnosed with Parkinson's Disease
Undergoing DBS as part of standard of care
Able to provide informed consent

Exclusion Criteria:
Age less than 18
General contraindications to surgery
Pregnant or nursing women
Unable to undergo MRI for any reason
Atypical Parkinsonism
Neurology
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

A Phase II/III Randomized Study of Maintenance Nivolumab versus Observation in Patients with Locally Advanced, Intermediate Risk HPV Positive OPCA (PSCI# 20-016) (EA3161)

The purpose of this study is to compare the usual treatment alone (radiation and chemotherapy) to adding maintenance nivolumab to the usual treatment. The addition of nivolumab to the usual treatment could shrink your cancer or prevent it from returning. But, it could also cause side effects, which are described in the risks section below.This study will help the study doctors find out if this different approach is better than the usual approach. To decide if it is better, the study doctors will be looking to see if the nivolumab increases the lifetime of the patient without progression for 10 years.This immunotherapy drug, nivolumab, is already approved by the FDA for use in advanced and incurable head and neck cancer. But, most of the time it is not used until the cancer is very advanced and chemotherapy stops working. In this study we believe the use of nivolumab has a chance of preventing the cancer from coming back for patients with your type of cancer. There will be about 286 people taking part in the first part (phase II) of the study and 458 more people taking part in second part (phase III), if the results of the phase II portion are promising and if there is evidence that nivolumab may prolong your life.

The purpose of this study is to compare the usual treatment alone (radiation and chemotherapy) to adding maintenance nivolumab to the usual treatment.

Yes
 

Mitchell Machtay
PSCI-CTO@pennstatehealth.psu.edu 717-531-5471
Medicine: Hematology and Medical Oncology (HERSHEY)
 

Male
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03811015
SITE00000750
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Age ≥ 18 years.
ECOG performance status of 0 or 1.
Patients must have oropharynx cancer that is p16-positive by immunohistochemistry
Adequate baseline organ and marrow function
Adequate baseline liver functionality

Exclusion Criteria:
Patients with a history of allergic reactions attributed to platinum based chemotherapy agents
Patients must not have had prior systemic therapy or radiation treatment for p16 positive OPSCC
Patients must not have received previous irradiation for head and neck, tumor, skull base, or brain tumors
Patients must not have known hypersensitivity to nivolumab
Patients with evidence of distant metastases or leptomeningeal disease are excluded
Cancer
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Interlimb differences in Motor Control and Learning

This study examines how each brain hemisphere contributes to motor control and coordination. Participants play virtual reality/computer games to look at how their arms move during different activities.

Yes
 

Robert Sainburg
Brooke Fosaaen - at sainburglab@psu.edu or 814-865-7937
Kinesiology (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
PRAMS00040722
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
over the age of 18

Exclusion Criteria:
neurological disease
upper-extremity orthopedic injuries that interfere with participation
Neurology, Sports Medicine, Muscle & Bone
I'm interested
Share via email
Show 2 locations

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,
State College, PA ,

Prevalence of Avoidant Restrictive Food Intake Disorder (ARFID) traits among children and adolescents with Food Allergy

This study looks at understanding eating behaviors and attitudes toward food in children/adolescents. More specifically the study's goal is to compare those with and without food allergies to gain a better understanding of a possible underlying factor towards certain behaviors. Children and their caregivers will complete a survey composed of a short section on the child's medical history regarding allergies followed with questions in commonly used clinical assessments.

No
 

Jodi Brady-Olympia
Jodi Brady-Olympia - at jbradyolympia@pennstatehealth.psu.edu or 717-531-1383
Pediatrics: General Pediatrics (HERSHEY)
 

All
Younger than 18 years old
This study is also accepting healthy volunteers
STUDY00015831
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Ages 8-17

Exclusion Criteria:
Age under 8 years old
Age 18 years or older
Intellectual disability preventing comprehension of questions
Child and/or caregiver unable to respond to English-language questionnaire
Children's Health, Allergies, Food & Nutrition
I'm interested
Share via email

Multidisciplinary Collaboration as a Bridge to the Ethical Collection of Patient-level Data on Social Determinants of Health (SDoH)

The purpose of this study is to create a tool that will evaluate a patients social determinants of health, which is the environment in which someone is born, works and lives. This tool could provide information to physicians that could help the patient avoid negative health outcomes.

Yes
 

Susan Veldheer
Brianna Hoglen - at bhoglen@pennstatehealth.psu.edu or 717-531-0003, ext=321654
Family and Community Medicine (HERSHEY)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00012893
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Adult 18+
Patient at Penn State Health OR Community Member
Can read and write in English

Exclusion Criteria:
Inability to make their own decisions/consent
prisoner
Brain Injury
Education
I'm interested
Share via email
Show 2 locations

Study Locations

Hide all locations
Location Contacts
Harrisburg, PA ,
Hershey, PA ,

Women, Opioid Use Disorder, and Criminal Justice: A Qualitative Study

Opioid-related overdose deaths and incarceration rates have skyrocketed and have disproportionately affected women. Despite having a higher burden of substance use disorders and HIV/AIDS than criminal justice-involved (CJI) men, CJI women are less likely to have access to substance use and HIV treatment. This qualitative study will conduct in-depth interviews with CJI women, MAT providers, and criminal justice professionals to identify facilitators and barriers to illicit opioid use cessation and related issues among CJI women.

No
 

Abenaa Jones
Abenaa Jones - at avj5462@psu.edu
Human Development and Family Studies (UNIVERSITY PARK)
 

Female
18 year(s) or older
This study is NOT accepting healthy volunteers
STUDY00018974
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
women
substance use
opioid use
criminal justice
drug treatment

Exclusion Criteria:
Younger than 18 years of age
Addiction & Substance Abuse, Mental & Behavioral Health, Women's Health
I'm interested
Share via email

Applying Social cognitive theories of learning to Adaptive Learning

In this work, we wish to explore how social learning can be promoted in the case of adaptive learning.

No
 

Sanjana Gautam
Sanjana Gautam - at sqg5699@psu.edu
Division of Graduate Studies (UNIVERSITY PARK)
 

Female
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00017614
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Above 18 years of age

Exclusion Criteria:
Below 18 years of age
Education
I'm interested
Share via email

Human-AI Interaction

We are conducting a series of focus groups to examine why people use technologies driven by artificial intelligence, and what gratifications people gain from those interactions. This is part of a larger project to understand human-AI interaction (HAII), a relatively new concept in the field of human-computer interaction. Our goal is to help pioneer a definition of HAII by first understanding the basics of how and why people use AI-driven technologies. Focus groups will consist of 5-10 people and will take no more than one hour to complete. All consenting adults near the State College area are welcome to participate.

Yes
 

S. Shyam Sundar
Carlina DiRusso - at cdd15@psu.edu
Film/Video and Media Studies (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00010500
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Adults ages 18 and older
Able to participate in-person in State College
Willing to discuss technology habits in a group setting

Exclusion Criteria:
Under the age of 18
Unable to attend in-person focus groups
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
State College, PA ,

Communicating Queer Chinese Identities: A Qualitative Investigation of the Visibility and Intelligibility of Transnational Queer Women in the United States

In today’s climate of anti-Asian hate, we believe that it is important to uncover different aspects of what “being Chinese” could look like. To this end, we are looking for individuals who self-identify as ethnically Chinese, woman, and a member of the LGBTQIA+ community to participate in a one-time 90-minute online interview to learn about what they do in their regular, everyday life to try to show or tell others about who they are. As part of the study, we will ask interviewees to share some visual images (e.g., photos, drawings, etc.) that they own as a way of elaborating on the ways that they communicate their self-identity in everyday life.

No
 

Terrie Wong
Terrie Wong - at terrie.wong@psu.edu
Academic Affairs (BRANDYWINE)
 

Female
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00018406
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
LGBTQIA+
Chinese ethnicity
Woman

Exclusion Criteria:
Heterosexual
Non-woman
Not Chinese ethnicity
Education, Language & Linguistics
I'm interested
Share via email

20-081, Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI5752 in Combo with Axitinib in Advanced RCC

Determine the maximum tolerated dose or maximum administered dose of MEDI5752 combined with axitinibAssess the safety and tolerability of MEDI5752 combined with axitinibAssess the antitumor activity of MEDI5752 combined with axitinib

The study will consist of 3 periods: screening, study treatment, and follow-up. You are expected to keep all of your study appointments and complete all study procedures.

$75 Per visit

Yes
 

Monika Joshi
PSCI-CTO@pennstatehealth@psu.edu 717-531-5471
Medicine: Hematology and Medical Oncology (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT04522323
SITE00000858
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Body weight > 35 kg
Histologically or cytologically proven advanced RCC
Advanced RCC not previously treated in that setting
Must have at least 1 measurable lesion according to RECIST v1.1
Life expectancy ≥ 12 weeks

Exclusion Criteria:
Previous treatment with axitinib
Previous treatment with mTOR inhibitors, PD-1, PD-L1, or CTLA-4 inhibitors for RCC
History of active primary immunodeficiency
History of organ transplant
Cancer
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

PSCI 21-176 Gilead ENHANCE 3 (GS-US-590-6154)

The purpose of this study is to see if magrolimab in combination with venetoclax and azacitidine is more effective than venetoclax and azacitidine in participants newly diagnosed with AML that are unfit for intensive chemotherapy.

Participants will be required to provide medical history, complete physical exam, laboratory tests, bone marrow biopsy and aspirate, ECOG, ECG, Echo or MUGA, pulmonary function tests, questionnaires, take study drug

Yes
 

Shin Mineishi
PSCI-CTO at PSCI-CTO@pennstatehealth.psu.edu or 717-531-5471
Medicine: Hematology and Medical Oncology (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT05079230
SITE00001311
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Previously untreated patients with histological confirmation of AML by WHO criteria who are ineligible for treatment with a standard cytarabine and anthracycline induction regimen due to age, or comorbidity.
ECOG performance status: a) Of 0 to 2 for subjects ≥ 75 years of age Or b) Of 0 to 3 for subjects ≥ 18 to 74 years of age
Patients with white blood cell (WBC) count ≤ 20  103/μL prior to randomization.
Hemoglobin must be ≥ 9 g/dL prior to initial dose of study treatment.
Patient has provided informed consent

Exclusion Criteria:
Positive serum pregnancy test
Breastfeeding female
Known hypersensitivity to any of the study drugs, the metabolites, or formulation excipient.
Patients receiving any live virus vaccine within 4 weeks prior to initiation of study treatments
Prior treatment with any of the following: a) CD47 or SIRPα-targeting agents
Cancer
Experimental drug compared to a placebo/”sugar pill”
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Public Perception of Public Health Wireless Emergency Alerts

The objectives of this study are to understand attitudes, emotional response, and behavioral intention related to receiving COVID-19 public health messaging via the Wireless Emergency Alert system.

No
 

Stephanie Madden
Stephanie Madden - at szm962@psu.edu or 316-305-7724
Advertising/Public Relations (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
STUDY00016799
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Resident of Pennsylvania
Received a Wireless Emergency Alert in November

Exclusion Criteria:
Not a resident of Pennsylvania
Did not receive a Wireless Emergency Alert in November
COVID-19, Prevention, Education
I'm interested
Share via email

Phase III IGRT and SBRT VS IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer (NRG-GU005) (PSCI# 19-073)

The purpose of this study is to compare any good and bad effects of using stereotactic body radiation therapy (SBRT), a technique that gives treatment in a shorter amount of time compared to the usual radiation therapy. SBRT is experimental for treating this type of cancer. SBRT uses special equipment to position a participant and precisely deliver radiation to tumors in the body. Both the study and the usual radiation treatments use daily images to guide the radiation treatment to protect normal tissue. The study treatment, treatment over a shorter amount of time, may prevent the tumor from returning but it could also cause side effects. This study will allow the researchers to know whether this different approach using SBRT is better, the same, or worse than the usual approach. To be better, the study treatment should increase the time without the cancer coming back by six months or more compared to the usual approach, and show improvements in side effects to the bladder or rectum.

The purpose of this study is to compare any good and bad effects of using stereotactic body radiation therapy (SBRT), a technique that gives treatment in a shorter amount of time compared to the usual radiation therapy. SBRT is experimental for treating this type of cancer. SBRT uses special equipment to position a participant and precisely deliver radiation to tumors in the body. Both the study and the usual radiation treatments use daily images to guide the radiation treatment to protect normal tissue. The study treatment, treatment over a shorter amount of time, may prevent the tumor from returning but it could also cause side effects. This study will allow the researchers to know whether this different approach using SBRT is better, the same, or worse than the usual approach. To be better, the study treatment should increase the time without the cancer coming back by six months or more compared to the usual approach, and show improvements in side effects to the bladder or rectum.

Yes
 

Joseph Miccio
Kathleen Rizzo - at krizzo@pennstatehealth.psu.edu or 717-531-0003, ext=289630
Radiation Oncology (HERSHEY)
 

Male
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03367702
SITE00000651
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
ECOG Performance Status 0-1 60 days prior to registration
Previously untreated localized adenocarcinoma of the prostate
Clinical stage by digital rectal exam of either T1c or T2a/b
The prostate volume must be < 60 cc as reported at time of biopsy or by separate measure with ultrasound or other imagining modalities including MRI or CT scan
Age is 18 years or older

Exclusion Criteria:
Definitive clinical or radiologic evidence of metastatic disease. No nodal involvement or evidence of metastatic disease allowed as defined by screening of the pelvis
Definitive T3 disease on MRI
Prior or current invasive malignancy with current evidence of active disease within the past 3 years
Prior systemic chemotherapy for the study cancer; note that prior chemotherapy for a different cancer is allowable; must be off treatment
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
Cancer
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Development of AI-Trust Model in Electronic Finances

The purpose of this study is to create a model that can predict a quantifiable change in human trust based on the performance of artificial intelligence. This is done through a 30 turn financial simulation where participants must invest "money" in stocks while being given the option to use or not use the assistance of an artificial intelligence.

No
 

Torsten Maier
Torsten Maier - at torstennamaier@psu.edu or 812-781-0014
Industrial and Manufacturing Engineering (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
STUDY00016151
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
English speaking/literate
18 years of age or older
Access to a computer

Exclusion Criteria:
Non-English speaking/literate
17 years of age or younger
No access to a computer
Education
I'm interested
Share via email

VIOLET: Vitamin D to Improve Outcomes by Leveraging Early Treatment

To assess the efficacy and safety of early administration of vitamin D3 (cholecalciferol) in reducing mortality and morbidity for vitamin D deficient patients at high risk for Acute Respiratory Distress Syndrome (ARDS) and mortality.

Yes
 

Jordan Schooler
Nancy Campbell RN - at ncampbell1@pennstatehealth.psu.edu or 717-531-1707, ext=3
Emergency Medicine (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03096314
SITE00000127
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Admission to ICU with acute risk factors for Acute Respiratory Distress Syndrome (ARDS): Pneumonia, Aspiration, smoke inhalation, lung contusion, hypoxemia, intubation
shock
sepsis
pancreatitis
Vit. D deficiency

Exclusion Criteria:
unable to take Vit D by mouth
blood Calcium levels > 10.2
known kidney stone in past 1 year
Do Not Rescusitate orders (DNR)
prisoner
Infectious Diseases & Immune System, Lung Disease & Asthma
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors (ELVCAP-001-01)(20-095)

Phase 2 Study of Seribantumab in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors

Most of the examinations, tests and procedures are part of the usual approach for your cancer. However, there will be extra procedures like blood draws and additional tests on your tumor to determine if your condition is suitable to take part in this study.There are three stages to this study: Screening, Study Treatment period, End of Study Treatment/Follow-up.

Yes
 

Patrick Ma
Irina Geier - at igeier@pennstatehealth.psu.edu
Medicine: Hematology and Medical Oncology (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT04383210
SITE00000889
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Locally-advanced or metastatic solid tumor with an NRG1 gene fusion
Availability of fresh or archived tumor sample
Minimum of one prior standard therapy appropriate for their tumor type and stage of disease, progressed or been nonresponsive to these available therapies
ECOG performance status 0, 1 or 2
At least one measurable extra-cranial lesion

Exclusion Criteria:
Non - NRG-1 mutations
Life expectancy < 3 months
Pregnant or lactating
Symptomatic or untreated brain metastases
Known hypersensitivity to any of the components of seribantumab
Cancer
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

What’s in a grammar? A microcomparative study of negation in American Englishes

In contexts where people speak different dialects of the same language, how much overlap is there between the dialects, and what are the genuine grammatical differences? This study explores this question through a series of three experiments examining how people from three different dialects understand a variety of negative sentences (e.g., I didn't eat nothing). The results will contribute to our understanding of linguistic diversity.

Participants will sit at a computer and have their eye movements tracked by a camera as they read or listen to sentences and look at pictures on the screen.

$15 per hour

Yes
 

Frances Blanchette
fkb1@psu.edu
Psychology (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00022446
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
native speaker of American English

Exclusion Criteria:
non-native speaker
not 18 or older
Language & Linguistics
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
State College, PA ,

Pilot evaluation of a multisensory evoked potential brain-computer interface

A brain-computer interface (BCI) is a device that has the potential to restore communication by translating voluntarily controlled brain signals of intent. The P300 speller, a popular BCI paradigm, relies on the generation of a P300 evoked potential when a user is presented a rare and unpredictable target stimulus amidst a larger pool of non-target stimuli. This evoked potential is used to control a spelling interface. Those with advanced ALS experiencing the loss of voluntary muscular control may also experience cognitive changes that result in decreased capacity for BCI control using the P300 speller.With this pilot study, we aim to validate the performance of a combination of eye tracking and standard sensory testing to quantify intact sensory and cognitive processes necessary for the generation of a P300 response. Additionally, we will evaluate the association of these correlates with performance on a multisensor P300 spelling task, where brain potentials are evoked using a combination of visual, auditory, and tactile stimuli. The goal is to demonstrate the viability of this system for future use in a patient group.

A brain-computer interface (BCI) is a device that has the potential to restore communication by direct translation of brain signals into computer commands. The BCI used in this study, the P300 Speller, relies on the generation of a P300 evoked potential when a user is presented a rare and unpredictable target stimulus amidst a larger pool of non-target stimuli. During this 2-hour, single session study, we aim to use a combination of eye tracking and sensory testing to quantify sensory and cognitive processes necessary for the generation of a P300 response. We will test the performance of a multisensory P300 spelling task, where brain potentials are evoked using a combination of visual, auditory, and tactile stimuli.

Yes
 

Andrew Geronimo
Andrew Geronimo - at ageronimo@pennstatehealth.psu.edu or 717-531-0003, ext=282576
Neurosurgery (HERSHEY)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00018219
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
18 years of age or older
Fluent in written and spoken English.

Exclusion Criteria:
Those unable to undergo electroencephalography (EEG) due to either allergies to lotions, cuts on the scalp or active infections.
History of seizure disorder
Co-existing neurological or psychiatric illness that, in the opinion of the research team, exclude the subject from participation.
Neurology
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

22-124 Main-CAV

To evaluate the effect of cabozantinib in combination with avelumab on OS compared to avelumab alone in patients with mUC who did not progress during first-line platinum-based chemotherapy therapy, i.e. patients who had CR, PR or SD after completion of first line platinum-based chemotherapy.

Patients will be expected to come to all clinic appointments, have labs drawn on the first day of every cycle, take medications as prescribed, return all empty pill bottles and diary, and call the clinic with questions.

Yes
 

Monika Joshi
PSCI-CTO at PSCI-CTO@pennstatehealth.psu.edu or 717-531-5471
Medicine: Hematology and Medical Oncology (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT05092958
SITE00001285
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Histologically or cytologically-confirmed diagnosis of advanced or metastatic urothelial cancer of the renal pelvis, ureter, bladder, or urethra
Prior first-line treatment must have consisted of 4-6 cycles of 1st-line therapy (platinum-based chemotherapy; gemcitabine-cisplatin, gemcitabine-carboplatin, MVAC or ddMVAC).
No prior immunotherapy with IL-2, IFN-α, or an anti-PD-1, anti-PD-L1, anti-PDL2, anti-CD137, or CTLA-4 antibody (including ipilimumab), or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways.
ECOG Performance Status of 0 or 1
Age ≥ 18 years

Exclusion Criteria:
Active autoimmune disease that might deteriorate when receiving the anti PD-L1 agent, avelumab.
No known symptomatic central nervous system (CNS) metastases.
No major surgery within 4 weeks prior to randomization.
No palliative radiotherapy within 48 hours prior to patient randomization.
No known cavitating pulmonary lesion(s) or known endobronchial disease manifestation.
Kidney & Urinary System, Cancer
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 2 locations

Study Locations

Hide all locations
Location Contacts
Harrisburg, PA ,
Hershey, PA ,

A Phase II/III Trial of De-intensified Radiation Therapy for Patients with Early-Stage, P16 Positive Oropharyngeal Cancer (NRG-HN005) (PSCI# 20-011)

The purpose of the first part of this study is to compare the usual treatment of a standard-dose radiation given over 6 weeks with cisplatin chemotherapy to a reduced-dose radiation given over either 6 weeks with cisplatin or 5 weeks with the immunotherapy drug, nivolumab. A lower dose of radiation as compared to the usual radiation treatment dose could be as effective in lengthening the time without your cancer getting worse. Nivolumab with reduced-dose radiation may or may not be as effective in lengthening the time without your cancer getting worse. This study will help the study doctors find out if this different approach is the same or worse than the usual approach.

The purpose of the first part of this study is to compare the usual treatment of a standard-dose radiation given over 6 weeks with cisplatin chemotherapy to a reduced-dose radiation given over either 6 weeks with cisplatin or 5 weeks with the immunotherapy drug, nivolumab. A lower dose of radiation as compared to the usual radiation treatment dose could be as effective in lengthening the time without your cancer getting worse. Nivolumab with reduced-dose radiation may or may not be as effective in lengthening the time without your cancer getting worse.This study will help the study doctors find out if this different approach is the same or worse than the usual approach.

Yes
 

Mitchell Machtay
PSCI-CTO@pennstatehealth.psu.edu 717-531-5471
Medicine: Hematology and Medical Oncology (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03952585
SITE00000721
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Pathologically proven diagnosis of squamous cell carcinoma of the oropharynx
Patients must have clinically or radiographically evident measurable disease at the primary site or at nodal stations
P16-positive based on local site immunohistochemical tissue staining
Zubrod Performance Status of 0-1 within 14 days prior to registration
Only English, Spanish, or French speaking patients are eligible to participate as these are the only languages for which the mandatory dysphagia-related patient reported instrument (MDADI) is available

Exclusion Criteria:
Clinical stages T0; T4; T1-2, N0; or any N2 (AJCC, 8th ed)
Recurrent disease
Definitive clinical or radiologic evidence of metastatic disease or adenopathy below the clavicles
Cancers considered to be from an oral cavity site or the nasopharynx, hypopharynx, or larynx, even if p16-positive, or histologies of adenosquamous, verrucous, or spindle cell carcinomas
Carcinoma of the neck of unknown primary site origin (T0 is ineligible, even if p16-positive)
Cancer
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 2 locations

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,
Reading, PA ,

Mechanisms of Cardiovascular Disease (MCD)

The primary objective of this protocol, Mechanisms of Cardiovascular Disease (MCD) is to collect biological specimens and data from patients with cardiovascular disease (CVD) to study the mechanisms that contribute to cardiovascular dysfunction and disease.

If you decide to participate in this study, you will be asked to provide a blood sample and possibly additional optional samples, either immediately or later. Additional samples may include saliva, cheek swab, urine, waste tissue or nasal swabs. You will decide whether you are willing to provide these other samples. Clinical data will be included in the dataset along with your sample.

Yes
 

Elisa Bradley
Omer Cavus - at ocavus@pennstatehealth.psu.edu or 717-531-0003, ext=320719
Medicine: Cardiology (HERSHEY)
 

All
All
This study is also accepting healthy volunteers
STUDY00019928
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
adults 18 years or older with or without cardiovascular disease
children less than 18 years with or without cardiovascular disease

Exclusion Criteria:
Prisoners are excluded from participation
Adult participants who are unable to provide a biologic sample
Heart & Vascular
Not applicable
I'm interested
Share via email
Show 6 locations

Study Locations

Hide all locations
Location Contacts
Harrisburg, PA ,
Hershey, PA ,
Reading, PA ,
State College, PA ,
Wilkes-Barre/Scranton Area, PA ,
York, PA ,

Endometriosis and microvascular dysfunction 3

Endometriosis, is a disorder that occurs in women, is when tissue that should be normally found inside the womb is also found in sites outside of the womb. Endometriosis is a disorder that is associated with systemic inflammation. This disorder impairs the function of the endothelium, the cells that line the body’s blood vessels (endothelium). The endothelium helps to control blood flow in healthy vessels. Women with endometriosis not only have an increased risk for high blood pressure and high cholesterol, they also have an increased risk for cardiovascular disease. With this study, we will learn how systemic inflammation in endometriosis impairs the lining of blood vessels and increases the risk for cardiovascular disease.We will use a short term intervention with a non-steroidal anti-inflammatory to examine how inflammation impact endothelial function in women with endometriosis

There will be 4 in person visits, at all visits blood will be drawn. Two of the visits will be experimental visits where we will measure skin blood flow and blood flow in the brachial artery. Participants will be required to take a placebo or the drug salsalate for 4 days prior to each experimental visit.

$450

Yes
 

Lacy Alexander
Susan Slimak - at sks31@psu.edu or 814-863-8556
Kinesiology (UNIVERSITY PARK)
 

Female
18 year(s) or older
This study is also accepting healthy volunteers
NCT05069740
STUDY00018369
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Women, 18-45 years of age
With and without Endometriosis

Exclusion Criteria:
Tobacco consumption (e.g. smoking)
Pregnant and/or breastfeeding
Taking blood pressure medication
Known allergy to Salsalate
Heart & Vascular, Pregnancy & Infertility, Women's Health
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 5 locations

Study Locations

Hide all locations
Location Contacts
Altoona, PA ,
Harrisburg, PA ,
Hershey, PA ,
State College, PA ,
Williamsport, PA ,

Return to Work Survey Development for Breast Cancer Survivors

The purpose of this study is to develop and test a survey to gain information that will improve our understanding of the return to work experience for breast cancer survivors. Study participants will answer questions on a questionnaire and undergo a one-on-one interview about those questions to ensure the wording and content is appropriate.

This is a questionnaire development study. Participants will be asked to complete a series of questions on a questionnaire form. Next, participants will sit for a one-on-one interview to discuss the questions and answer choices on the questionnaire.

Yes
 

Meghan Vidt
Jared Heitzenrater - at jheitzenrater@pennstatehealth.psu.edu or 717-531-0003, ext=323324
Biomedical Engineering (UNIVERSITY PARK)
 

Female
18 year(s) or older
This study is NOT accepting healthy volunteers
STUDY00019881
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Previous diagnosis of breast cancer, stage 0-III
Last cancer treatment was 2-5 years ago
Received breast cancer treatment at Penn State Health
Employed outside the home at least part time (>20hr/wk) before and after cancer treatment

Exclusion Criteria:
Last cancer treatment was less than 2 years or greater than 5 years ago
Underwent prophylactic treatment due to increased risk, such as testing positive for BRCA gene (breast cancer)
Unemployed or does not participate in the workforce for pay either before or after cancer
Currently being treated for any type of cancer
Has experienced a work-related injury that does not allow work, is receiving Worker's Compensation, or is currently in litigation for work-related injury
Cancer
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

A Phase 1/2, Open-label, Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity Study of Repotrectinib in Pediatric and Young Adult Subjects with Advanced or Metastatic Malignancies Harboring ALK, ROS1, or NTRK1-3 Alterations (CARE)

Repotrectinib for cancer that has returned or is not responding to treatment

If you agree to take part in this study, you will need to visit the study site regularly and follow the study procedures listed later in this document. You will be told what these procedures are and why they are needed. These procedures include interviews, exams, heart testing, tumor assessments, and blood and urine samples. You will be asked to take the study drug Repotrectinib. This is a capsule to be taken orally.

Yes
 

Valerie Brown
Suzanne Treadway - at streadway@pennstatehelath.psu.edu or 717-531-3097
Pediatrics: Hematology/Oncology (HERSHEY)
 

All
All
This study is NOT accepting healthy volunteers
NCT04094610
STUDY00014715
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
You have cancer that has returned or is not respondin g to treatment
You are positive for certain changes in your genes which we will test you for as needed

Exclusion Criteria:
1. You have gastrointestinal disease, such as Crohn’s disease,
Cancer
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,